Parkinson's News Today

The Parkinson's Foundation reports that every year, between 50,000 and 60,000 new cases of Parkinson's disease (PD) are identified in the U.S., adding to the existing one million individuals living with this condition. Parkinson's News Today is a daily online publication focused on delivering news about the science, research, and advocacy related to Parkinson's disease. Our writing team consists of both PhDs and experienced journalists, enabling us to present scientific information in a way that is accessible and easy for patients to comprehend.

Consumer

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#564311

United States

#173172

Health/Health Conditions and Concerns

#432

Traffic sources

Monthly visitors

Articles

Study findings 'lay foundation' for targeted therapies in Parkinson's

1 week ago | parkinsonsnewstoday.com | Margarida Maia

A small molecule called NK036 — which inhibits USP30, an enzyme that counters the removal of damaged mitochondria from nerve cells in Parkinson’s disease — fits tightly into its target, suggesting it may have a strong and lasting effect as a treatment for the neurological condition, a new study found.
MJFF expands fellowship for training movement disorder specialists

1 week ago | parkinsonsnewstoday.com | Andrea Lobo

The Michael J. Fox Foundation (MJFF) is expanding the size and reach of its global Edmond J. Safra Fellowship in Movement Disorders program, which trains specialists in improving access to Parkinson’s disease care. The program provides funding each year for medical centers to train physicians to become Parkinson’s specialists. These movement disorder specialists are neurologists with additional training in diagnosing and treating Parkinson’s disease.
RNA-editing enzyme ADAR1 may be new Parkinson's target

1 week ago | parkinsonsnewstoday.com | Andrea Lobo

The dysregulation of RNA editing within astrocytes (neuron-supporting cells) seems to induce chronic inflammation and ultimately contributes to the loss of nerve cells in people with Parkinson’s disease, according to a recent study. This dysregulation is triggered by alpha-synuclein clumping, which is a characteristic feature of Parkinson’s.
Compound identified that may reduce Parkinson's disease brain inflammation

1 week ago | parkinsonsnewstoday.com | Marisa Wexler

An experimental compound has been identified that shows the potential to reduce brain inflammation in neurodegenerative conditions such as Parkinson’s disease. MFP-0012328 works by blocking FABP4, a protein that researchers have shown to be key in the inflammatory activity of microglia, the brain’s immune cells. While other FABP4 suppressors have been studied, this one appears to show the most pronounced effects and favorable properties for reaching the brain.
New insights into motor control in brain may help in Parkinson’s

1 week ago | parkinsonsnewstoday.com | Steve Bryson

Switching actions and stopping movements involve two distinct cognitive motor processes, according to a study that combined computer modeling with tasks performed by healthy people. The findings have implications for people with Parkinson’s disease, who experience longer reaction times and delays when they want to start, stop, or switch movements, the researchers said.
Exercise, fall risk, caregiver burden focus of UAMS Parkinson’s symposium

1 week ago | parkinsonsnewstoday.com | Andrea Lobo

Physical exercise, avoiding falls, and the importance of providing support to caregivers were the focus of the 10th UAMS Parkinson’s symposium hosted last month by the University of Arkansas for Medical Sciences (UAMS), where the latest advances in diagnosing and treating people with Parkinson’s disease and atypical parkinsonism were also shared.
Psilocybin eases depression, anxiety in Parkinson's: Pilot trial

1 week ago | parkinsonsnewstoday.com | Andrea Lobo

Low-dose psilocybin, a naturally occurring psychedelic compound, may be a promising therapy for mood issues including depression and anxiety in people with Parkinson’s disease, according to data from a pilot Phase 2 clinical trial. In addition to significant reductions in depression and anxiety, results from the trial (NCT04932434) pointed to psilocybin’s potential benefits for patients’ cognitive and motor function.
IC 100 lowers inflammasome activation, alpha-synuclein clumps in Parkinson's

1 week ago | parkinsonsnewstoday.com | Andrea Lobo

Blocking the inflammatory protein ASC with IC 100, ZyVersa Therapeutics’ experimental therapy to reduce inflammation, prevented the activation of the inflammasome in microglia — the brain’s resident immune cells — and the start and perpetuation of an inflammatory response. That’s according to results from a study announced by the company that also showed IC 100 was able to reduce alpha-synuclein aggregation, a hallmark of Parkinson’s disease that contributes to neurodegeneration.
Walking to music helps Parkinson's patients walk more, gain healthy habits

1 week ago | parkinsonsnewstoday.com | Margarida Maia

Listening to rhythm-based cues while walking not only builds lasting walking habits, but also helps people with Parkinson’s disease walk more, at a greater intensity, and more steadily than walking on their own. These are the findings of a clinical study (NCT05421624) that tested MR-005, a digital tool from MedRhythms that uses music to help set the pace for walking, so that a person can match their steps to the beat they hear.
Guest Voice: When the caregiver becomes the one in need of care

2 weeks ago | parkinsonsnewstoday.com | Rosalba Mancuso

Rosalba Mancuso is a bilingual freelance journalist based in Sicily. Writing in English and Italian, she has contributed to national magazines and newspapers for over 30 years, as well as international publications. She also dedicates her writing to spreading awareness about living with Parkinson’s disease. Getting Parkinson’s is not an enjoyable experience for anyone, particularly when you’re young. It’s not something that’s predictable, either.